{"name":"Jasper Therapeutics","slug":"jasper","ticker":"JSPR","exchange":"NASDAQ","domain":"jaspertherapeutics.com","description":"Jasper Therapeutics is a biopharmaceutical company focused on developing therapies for hematological and oncological disorders. The company's lead product candidate, JSP191, is a CD117-targeting antibody-drug conjugate being developed for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. Jasper Therapeutics has a strong pipeline of product candidates in various stages of development, with a focus on addressing unmet medical needs in the hematology and oncology therapeutic areas.","hq":"Redwood City, CA","founded":0,"employees":"","ceo":"Ronald Martell","sector":"Hematology / Transplant","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.4B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":55821000,"netIncome":-71269000,"cash":79899000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"JSP191 patent cliff ($0.0B at risk)","drug":"JSP191","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Jasper Therapeutics Announces FDA Clearance of IND for JSP191","summary":"Jasper Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for JSP191, a CD117-targeting antibody-drug conjugate being developed for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.","drugName":"JSP191","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Jasper Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Jasper Therapeutics reported its financial results for the third quarter of 2023, with a net loss of $14.4 million and a cash and cash equivalents balance of $143.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-15","type":"deal","headline":"Jasper Therapeutics Announces Collaboration with National Cancer Institute","summary":"Jasper Therapeutics announced a collaboration with the National Cancer Institute (NCI) to develop and commercialize JSP191, a CD117-targeting antibody-drug conjugate being developed for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPbnpMUHVYcVhHNHZLWFA0S1lmNGdXVjBmNmNxUmxnbU1yVkVtUWtZeVRsSHJkLVRUV254YU5sSXNUM291SlZxTmEwc1FvUlhQckhmT0p4eVFobFBkZTdWMURpb2ZvaHdmekVyczJOWF81a2U2YTNLeURDWUI0OXlQUXh0aTI?oc=5","date":"2026-03-31","type":"earnings","source":"AlphaStreet","summary":"Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - AlphaStreet","headline":"Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX0tzVTdqZVRHa1VyUkxHdXZBUWNqVXpxb2ZIMGI0bTMwOWZ4NnhIaXVLVjhzeXBSblF4elhyM2hJeFRkNmRiNUFzMUQ4TkFUR3dKbXNmQVFzaWFKN2NmTUt3NDFFV0U5MldmcUM3Y193UkhtMTZrYjBKQVk2Z3gzSHExUEpmak42b3JQWkU1eW1fUmFFLXgxemZCVnhjeE9NM01OcW45bEQ5TGhETDlINXRodGtEaXNCdlI4?oc=5","date":"2026-03-30","type":"pipeline","source":"Defense World","summary":"Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $34.00 - Defense World","headline":"Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $34.00","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOdy1IR0tvZ25HUGowMjByem5DQzdpYWt4WWpIUEZwMGNueG5LSmtBNXJMWFFkN0pfV3VuSnBlX0UxOVZWdllZLXRQb1VjbVg3eXpLd0ZrMUlySzc3NFhQYmRzQ2xLS1hCMmNPSGU4SWpYUHF3MV9icDI4RnNKeEludUZJMWdHYnVPMVZBZWp1T2l3NkZZakRPTjVnWmlZbk83bm13N3RjdXhxbk9oVFpVdWhubzQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - simplywall.st","headline":"Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNRlA4dm1nVThpUExUMWt4dlRReDVabE9rS0U4dmRPZEI4VkhUVFlzRndnSE1pNFhDZHF3Nl9SVVdfaGRNMnNobFpBd1pJdzJzVDZ1c3RwUnlIckM3ZXc1STlndDA5cmtXVnVfVmVfZm55ZW5tRHk2UFJwXzNXYVR5R0p1OUg1N3JhYVY4VnFEaU5PSHRpRk91eVEySjYzdWFBVXk5QjFYTzlDVVNJc05QemM3djJoeHNkVFV0MTVVVXBtNEE?oc=5","date":"2025-12-31","type":"pipeline","source":"AD HOC NEWS","summary":"Jasper Therapeutics: Volatile Small-Cap Biotech Tests Investor Nerves As The Year Closes - AD HOC NEWS","headline":"Jasper Therapeutics: Volatile Small-Cap Biotech Tests Investor Nerves As The Year Closes","sentiment":"neutral"},{"date":"2025-12-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"pipeline","source":"simplywall.st","summary":"Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k - simplywall.st","headline":"Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOV2ZVcElOaTJVaDF2clVOWTNzSkhkVWZXRzM0RGlTbEtJbWdpdTRMYlE0RjZialhrcFNSSXRjaGs0VFVsNlZvdFplV2pwOGR3bko1Z0RWTjc5SW5aaGVhdlJsRmpqcTJPd2Jib0o4UUtmZHlPSG54R2JsSzcxOUMtVHVaem5rZDdxb2hUV3BKaldlU1Y5bWxkTWh1UklyX1ZOblAtVmJtcXRMMlFOamhWYXlObHNUZFk0WnFXelFtMUVCTkxxUmJrdUNLZTQzQVZnbndRbWYyZ1ZOLXUxeGtPQUczR0dhUEU?oc=5","date":"2025-08-27","type":"trial","source":"reuters.com","summary":"Health Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trial - reuters.com","headline":"Health Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zc0NUNVB0dU95ZHRFRG1tVE9NTWxkNmJxaHl5c2pjZndYZ0tzS0UtTWd4OVhiTmJEOXppQ3ljcEZUZ3lKOXRLZFBTRUVhWWJmVGpz?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"JSPR Stock Price, News & Analysis - Stock Titan","headline":"JSPR Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"JSP191","drugSlug":"cd117-targeting-antibody-drug-conjugate","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Celgene","Gilead Sciences"],"therapeuticFocus":["Hematology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":55821000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-71269000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":79899000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}